Skip to main content
Novacyt logo

Novacyt — Investor Relations & Filings

Ticker · ALNOV ISIN · FR0010397232 LEI · 213800BWAC2BF295EG28 PA Manufacturing
Open in API
Filings indexed 1,101 across all filing types
Latest filing 2022-10-26 Regulatory Filings
Country FR France
Listing PA ALNOV

About Novacyt

https://novacyt.com/

Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services. The company's core activities include the design, development, manufacturing, and commercialization of in vitro and molecular diagnostic tests, with a specialization in real-time PCR (qPCR) kits and reagents. Novacyt's solutions are applied across various markets, including clinical diagnostics for human health, with a focus on infectious diseases and oncology, as well as animal health and food safety. The company also offers custom development services, contract manufacturing, and pharmaceutical research services such as whole genome sequencing.

Recent filings

Filing Released Lang Actions
UK Approval of genesig® SARS-CoV-2 Winterplex® 3G
Regulatory Filings Classification · 100% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) on October 26, 2022. The content details the approval of a specific diagnostic test (genesig® SARS-CoV-2 Winterplex® 3 Gene assay panel) in the UK under CTDA legislation. This is a specific operational update concerning regulatory compliance and product status, rather than a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is a specific regulatory/operational announcement that doesn't fit the other specialized categories (like DIRS, DIV, CAP), the most appropriate general category for regulatory news updates that are not financial results or shareholder meetings is 'Regulatory Filings' (RNS). It is not a Report Publication Announcement (RPA) because it is announcing an event/approval, not the publication of a separate, attached report.
2022-10-26 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 26, 2022, announcing that Novacyt's genesig® SARS-CoV-2 Winterplex® 3G test panel received approval under the UK's CTDA regulation. This is a specific, material operational/regulatory update concerning product clearance, not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is an announcement of a regulatory milestone. While it could potentially fall under 'Regulatory Filings' (RNS), the content is highly specific to a product approval/clearance, which is a type of corporate event announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for specific regulatory milestones that aren't standard financial reports or director dealings. However, since the core subject is a regulatory approval for a diagnostic test, and it is not a financial report, 'RNS' serves as the best fit among the provided codes for a non-financial, specific regulatory announcement.
2022-10-26 French
Inside Information / Operations of the issuer (acquisitions, sales...)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 26, 2022, announcing that Novacyt's genesig® SARS-CoV-2 Winterplex® 3 Gene assay panel has been approved in the UK under CTDA legislation. This is a specific operational update regarding product regulatory status and market access, not a comprehensive financial report (10-K, IR), a management change (MANG), or a general earnings announcement (ER). The content focuses on a regulatory approval specific to a diagnostic test, which aligns best with a general regulatory announcement or operational update. Since there is no specific category for 'Product Regulatory Approval', and it is a formal announcement of a regulatory milestone, it fits best under 'Regulatory Filings' (RNS) as a miscellaneous regulatory announcement, or potentially 'Capital/Financing Update' (CAP) if the approval directly impacts sales/financing, but RNS is the most appropriate fallback for specific regulatory milestones that aren't financial reports or insider trades. Given the explicit mention of 'CTDA legislation' and the nature of the announcement, RNS is the best fit among the provided options for a non-financial, non-governance regulatory update.
2022-10-26 English
Liquidity Agreement and Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement disseminated via RNS (RNS Number: 6022B) from Novacyt S.A. The content explicitly covers two main topics: 1) A 'Liquidity Agreement Monthly Update' detailing share purchases and sales under a liquidity agreement, and 2) The 'Total Voting Rights' figure for the company as of September 30, 2022. Announcements regarding share transactions (like liquidity agreements or treasury share movements) and the total number of voting rights are typically classified as general regulatory disclosures or specific corporate actions. Since it details share transactions (POS activity) and provides the denominator for shareholder notifications (related to voting rights/ownership changes), it fits best under the general 'Regulatory Filings' (RNS) category as a routine disclosure, or potentially 'Transaction in Own Shares' (POS) due to the liquidity agreement details. However, the inclusion of the Total Voting Rights calculation denominator (a common requirement for regulatory updates) and the RNS header strongly suggest a broad regulatory filing. Given the dual nature (liquidity/treasury shares + voting rights), and the fact that it is a routine monthly update rather than a major capital change (SHA) or a specific insider trade report (DIRS), RNS is the most appropriate general classification for this type of routine market disclosure. Checking definitions: It is not an ER, IR, 10-K, or AR. It is a regulatory update. It is not a DEF 14A (Remuneration) or DVA (Voting Results). It is a routine update on share activity and voting rights, making RNS the best fit as a general regulatory announcement.
2022-10-03 English
Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote" (Monthly information on the liquidity contract and on the total number of voting rights). It details the activity under a liquidity contract (share buybacks/sales) for the period September 1 to September 30, 2022, and reports the total number of voting rights (70,626,248 shares). This type of regular, periodic disclosure concerning share transactions (often related to market making or treasury stock management) and total share count is characteristic of specific regulatory updates, but it does not fit neatly into the primary financial reports (10-K, IR) or standard corporate actions (DIV, SHA). It is a specific regulatory disclosure concerning share structure and market activity. Since it is a specific, recurring report on share transactions and voting rights, it is best classified as a Regulatory Filing (RNS) as a general category for specific, non-core financial disclosures, or potentially related to Director's Dealing (DIRS) if the transactions were executive-driven, but here it is explicitly about a liquidity contract managed by a third party (Invest Securities). Given the options, RNS serves as the most appropriate catch-all for this specific monthly regulatory update that isn't a standard financial report or a director's personal trade report.
2022-10-03 French
Half year 2022 results
Earnings Release Classification · 100% confidence The document explicitly states it announces the "unaudited results for the six months ended 30 June 2022." It contains detailed financial highlights, including revenue, gross profit, EBITDA, and a comparative table for H1 2022 vs H1 2021. This content structure is characteristic of a comprehensive financial report covering a period shorter than a full year. The classification 'Interim / Quarterly Report' (IR) is the most appropriate fit for a 'Half year' results announcement. H1 2022
2022-09-29 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.